London-listed pharmaceutical & healthcare giant GlaxoSmithKline (GSK) Plc has announced a $940-million (Rs 5,220-crore) open offer to raise its stake in its Indian subsidiary GlaxoSmithKline Consumer Healthcare.

On Monday, GlaxoSmithKline Plc announced that it wanted to acquire up to 13,389,410 shares of GlaxoSmithKline Consumer Healthcare, increasing its stake in the company by 31.8 per cent, from 43.2 per cent to 75 per cent.

The open offer represents a premium of 28 per cent to Friday's closing price of the stock.

Analysts are of the view that the deal would be beneficial for shareholders as well as the Indian company, which would get access to more resources from the parent company.

Analysts Shirish Pardeshi and Aniruddha Joshi, of Anand Rathi, said, "The open offer indicates higher commitment from promoters. We expect higher new launches from promoters' stable and greater sharing of technology and resources."

GlaxoSmithKline Consumer Healthcare, which is known for its Boost and Horlicks brands in India, will keep on receiving new products as well as technology from the parent company, regardless of the response to the offer.

Following the GlaxoSmithKline Plc's announcement, the stock in GlaxoSmithKline Consumer Healthcare gained Rs 608 to Rs 3,651.80 a share on Monday.